lymphocyte-mediated

Ponesimod (ACT-128800) is an orally available sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) agonist with potential immunomodulating activity.

Salicyl alcohol is an inhibitor of lymphocyte-mediated cell lysis from prunes.

Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

2-Fluoroadenosine is a potent inhibitor of lymphocyte-mediated cytolysis.

FTY720 (S)-Phosphate is the active stereoisomeric phosphate derivative of FTY720 that acts as a potent modulator of sphingosine-1-phosphate (S1P) receptors. FTY720 (S)-Phosphate binds to S1P receptor subtypes S1P1, S1P3, S1P4, and S1P5 with Ki values of 2.1, 5.9, 23, and 2.2 nM respectively, causing receptor internalization on lymphocytes， preventing S1P-mediated lymphocyte egress from lymphoid tissues. FTY720 (S)-Phosphate also enhances endothelial barrier integrity, stimulates transporters such as Abcb1 and Abcc1, and inhibits cytosolic phospholipase A2 activity, highlighting its multifunctional pharmacological properties, making it an compound of interest in the research of diseases including multiple sclerosis, autoimmune diseases and cancer.

PF-07265028 is a highly potent and selective small-molecule inhibitor of hematopoietic progenitor cell kinase 1 (HPK1/MAP4K1). By blocking HPK1-mediated signal transduction, PF-07265028 enhances T-cell receptor-associated signaling, thereby lifting immune suppression and promoting antitumor immune responses. PF-07265028 exhibits significant activity at the cellular level (e.g., inhibition of pSLP76, IC₅₀ approximately 17 nM). PF-07265028 is suitable for use in cancer research.

Sch 24937 is a potent immunosuppressant on B lymphocyte mediated immune responses.

3-Deaza-2'-deoxyadenosine is a nucleoside analog synthesized from 2'-deoxyadenosine.3-Deaza-2'-deoxyadenosine inhibits RNA synthesis by binding to the ribose moiety of ribonucleotides, preventing the formation of enzyme-substrate complexes and chain elongation.It can also inhibit DNA synthesis by binding to the deoxyribose moiety of DNA and blocking the addition of nucleotides to the growing chain by DNA polymerases.3-Deaza-2'-deoxyadenosine exhibits antiviral activity.

Lifitegrast sodium (SAR-1118-023 sodium) is a small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), which reduces inflammation of the ocular surface, and may be used in the study of dry eye.

DOCK2-IN-1 is a selective DOCK2 inhibitor (IC50 = 0.51 μM). It suppresses lymphocyte migration and cytoskeleton reorganization by blocking DOCK2-mediated Rac activation, used for immune response and transplant rejection research.

Trichomide A, a natural cyclodepsipeptide, serves as a potent activator of SHP2. This compound exhibits immunosuppressive activity against activated T lymphocyte-mediated immune responses in Con A-activated T cells, highlighting its potential utility in researching immune-related skin diseases [1].

Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody that targets cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) and antagonizes CTLA-4–mediated inhibitory immune checkpoints, thereby enhancing immune cell activation, Zalifrelimab is widely used in immuno-oncology research to study immune checkpoint blockade and antitumor immune responses.

Finotonlimab is a highly specialized recombinant humanized monoclonal antibody of the immunoglobulin G4 isotype target the human programmed cell death protein 1 receptor with exceptional binding affinity and selectivity, restoration of T-lymphocyte mediated anti-tumor immunity by disrupting the inhibitory signaling axis established through interactions with PD-L1 and PD-L2 ligands across various preclinical and clinical experimental models of advanced solid malignancies.

Keliximab (SB-210396), a chimeric human/macaque anti-CD4 monoclonal antibody, demonstrates binding affinity for soluble CD4 with a Ki value of 1.0 nM. Keliximab (SB-210396) inhibits T-cell proliferation and IL-2 production, making Keliximab (SB-210396) a valuable reagent for cancer research and immune signaling investigations. Keliximab (SB-210396) is additionally applicable to studies involving CD4-mediated immune activation and lymphocyte functional regulation.

Tifcemalimab (JS004) is a humanised antibody targeting BTLA (B and T lymphocyte attenuator), which binds to BTLA and blocks the interaction between HVEM and BTLA, exhibiting immunomodulatory and antitumour activity.

R707 is a humanized monoclonal antibody expressed in CHO cells targeting C-C chemokine receptor type 7 (CCR7/CD197). R707 specifically binds to CCR7, blocking its interaction with ligands CCL19 and CCL21. This blockade inhibits CCR7-mediated cell migration, chemotaxis, and lymphocyte homing to lymph nodes. It exhibits significant biological activity in researching chronic lymphocytic leukemia (CLL), autoimmune diseases, and lymph node metastasis of tumor cells.

Ponesimod-D7 is the deuterium-labeled form of Ponesimod (T3258). It is an effective, selective, and orally active agonist of S1P1, with an IC50 value of 6 nM in radioligand binding assays. Ponesimod-D7 efficiently activates S1P1-mediated signal transduction with an EC50 of 5.7 nM and can prevent lymphocyte-mediated tissue inflammation.

Acalabrutinib-D4 is a deuterated compound of Acalabrutinib. Acalabrutinib (T3626) has a CAS number of 1420477-60-6. Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

Kp7-6 is a Fas mimetic peptide that disrupts receptor complexes by simultaneously binding to Fas and FasL, thereby blocking downstream apoptotic signaling. Kp7-6 inhibits ERK1-2 phosphorylation, induces IκBα phosphorylation, and activates NF-κB. Kp7-6 suppresses the activation of caspase-8, caspase-3, and JNK, reduces human amylin-induced β-cell apoptosis, and decreases FasL-mediated lymphocyte cytotoxicity and apoptosis. In pancreatic neuroendocrine tumor models, Kp7-6 downregulates local FasL expression, increases CD8+Fas+ T-cell infiltration, and reduces tumor volume. Kp7-6 prevents concanavalin A-induced liver injury in mice and is applicable to research on type 2 diabetes, hepatitis, and pancreatic neuroendocrine tumors.